Management Change/Compensation (Form 8-K)

Item 5.02 - Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Mr. Kenneth Perry Chief Financial Officer was placed on administrative suspension with pay effective March 31, 2026. Following the Committee's review and recommendation, the Independent Board of Directors approved the termination of Mr. Perry's employment for Cause, with notice of such termination delivered on May 2, 2026.

On April 27, 2026 the Board of Directors (the "Board") of (the "Company"), acting upon the recommendation of its Governance and Nominating Committee (the "Committee"), determined that the conduct of the Company's Chief Financial Officer, Kenneth Perry, constituted a material and continuing breach of his Employment Agreement and satisfied the definition of "Cause" as set forth therein.

The Committee, which is comprised of three independent advisors, conducted a comprehensive review of relevant materials, including audit-related findings, Board records, and documented communications. Upon completion of its review, the Committee submitted its findings and formal recommendation to the independent members of the Board. A meeting of the independent members of the Board was held on April 27, 2026, at which two of the three directors were present. The Company's Chief Executive Officer recused himself from all deliberations and decisions related to this matter.

In connection with the foregoing, on April 1, 2026, the Board appointed Don E. Ray to serve as Interim Chief Financial Officer of the Company. Mr. Ray's appointment is for an initial term of 90 days.

Contact: Regenerex Pharma, Inc.

Company Ph: 877-761-RGPX (7479)

Investor Relations Ph: (305) 927-5191

Email: [email protected]

regenerexpharmainc.com